(Sharecast News) - The share price of AIM-listed Arecor Therapeutics dropped by almost a third on Monday after the biopharma firm warned that its working capital requirements had "accelerated" while full-year revenues remain highly uncertain.
The company, which stated earlier in the year that it needed additional funding, said that the...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE